The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
Abstract
Anemia resulting from cancer, or its treatment, is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin. To address uncertainties regarding indications and efficacy, the American Society of Clinical Oncology and the American Society of Hematology developed an evidence-based clinical practice guideline for the use of epoetin in patients with cancer. The guideline panel found good evidence to recommend use of epoetin as a treatment option for patients with chemotherapy-associated anemia with a hemoglobin level less than 10 g/dL. Use of epoetin for patients with less severe anemia (hemoglobin < 12 g/dL but never below 10 g/dL) should be determined by clinical circumstances. Good evidence from clinical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg tiw) for a minimum of 4 weeks. Less strong evidence supports an alternative weekly (40,000 U/wk) dosing regimen, based on common clinical practice. With either administration schedule, dose escalation should be considered for those not responding to the initial dose. In the absence of response, continuing epoetin beyond 6 to 8 weeks does not appear to be beneficial. Epoetin should be titrated once the hemoglobin concentration reaches 12 g/dL. Evidence from one randomized controlled trial supports use of epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy; however, there are no published high-quality studies to support its use for anemia in other hematologic malignancies in the absence of chemotherapy. Therefore, for anemic patients with hematologic malignancies, it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citationBesarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Self-citationGlaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2875 · Cited by 595
Cella, D., Hahn, E. A., & Dineen, K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523
Self-citation(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.671 · Cited by 431
Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., & Messinger, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.131 · Cited by 310
Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis
Kaufman, J. S., Reda, D. J., Fye, C. L., Goldfarb, D. S., Henderson, W. G., Kleinman, J. G., & Vaamonde, C. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390902 · Cited by 300
Seidenfeld, J., Piper, M., Flamm, C., Hasselblad, V., Armitage, J. O., Bennett, C. L., Gordon, M. S., Lichtin, A. E., Wade, J. L., Woolf, S., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1204 · Cited by 222
Self-citationOsterborg, A., Boogaerts, M., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A., & Peest, D. (1996) · Blood · doi:10.1182/blood.v87.7.2675.bloodjournal8772675 · Cited by 202
Cascinu, S., Fedeli, A., Ferro, E. D., Fedeli, S. L., & Catalano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1058 · Cited by 194
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
Dammacco, F., Castoldi, G., & Rödjer, S. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02715.x · Cited by 181
yndromes, I. T. C. O. S. T. G. R. R. I. M. Y. S. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01085.x · Cited by 174
Henry, D. H., & Abels, R. I. (1994) · PubMed · Cited by 159
Mastro, L. D., Venturini, M., Lionetto, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2715 · Cited by 130
Thatcher, N. J., Campos, E. S. D., Bell, D., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690369 · Cited by 129
Erythropoietin increases hemoglobin in cancer patients during radiation therapy
Lavey, R. S., & Dempsey, W. H. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90536-5 · Cited by 123
Cheung, W. K., Goon, B. L., Guilfoyle, M. C., & Wacholtz, M. C. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90072-8 · Cited by 112
Respiratory Diseases from Hard Metal or Cobalt Exposure
Demedts, M., & Ceuppens, J. L. (1989) · CHEST Journal · doi:10.1378/chest.95.1.2 · Cited by 99
Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly
Cheung, W. K., Minton, N. A., & Gunawardena, K. A. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100324 · Cited by 96
Garton, J. P., Gertz, M. A., Witzig, T. E., Greipp, P. R., Lust, J. A., Schroeder, G., & Kyle, R. A. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.19.2069 · Cited by 96
Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer
Abels, R. I., Larholt, K. M., Krantz, K. D., & Bryant, E. C. (1991) · Stem Cells · doi:10.1002/stem.5530090714 · Cited by 93
Glaspy, J. A., Jadeja, J., Justice, G. R., Kessler, J., Richards, D., Schwartzberg, L. S., Rigas, J. R., Kuter, D. J., Harmon, D. C., Prow, D. M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1748 · Cited by 82
Sweeney, P., Nicolae, D. L., Ignacio, L., Chen, L., Roach, M., Wara, W., Marcus, K. J., & Vijayakumar, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.331 · Cited by 72
Porter, J. C., Leahey, A., Polise, K., Bunin, G. R., & Manno, C. S. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70145-2 · Cited by 66
Kurz, C., Marth, C., Windbichler, G. H., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4675 · Cited by 54
Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
Silvestris, F., Romito, A., Fanelli, P., Vacca, A., & Dammacco, F. (1995) · Annals of Hematology · doi:10.1007/bf01696618 · Cited by 52
Kreuzer, K. ‐., ROCKSTROH, J. ̈. K., JELKMANN, W. E. B., Theisen, A., Spengler, U., & SAUERBRUCH, T. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2031.x · Cited by 52
Dammacco, F., Silvestris, F., Castoldi, G., Grassi, B., Bernasconi, C., Nadali, G., Perona, G., Laurenzi, A. D., Torelli, U. L., Ascari, E., et al. (1998) · International Journal of Clinical & Laboratory Research · doi:10.1007/s005990050032 · Cited by 48
Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer
Abels, R. I., Larholt, K. M., Krantz, K. D., & Bryant, E. C. (1996) · The Oncologist · doi:10.1634/theoncologist.1-3-140 · Cited by 44
Wurnig, C., Windhager, R., Schwameis, E., Kotz, R. I., Zoubek, A., Stockenhuber, F., & Kurz, R. W. (1996) · Transfusion · doi:10.1046/j.1537-2995.1996.36296181929.x · Cited by 43
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch, R., James, R. D., Wilkinson, P. M., et al. (2006) · PubMed · Cited by 40
Cited by
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
Self-citationWeiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Metadata
- Authors
- Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., Miller, C. B., Rarick, M. U., Regan, D. H., Browman, G. P., & Gordon, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-10-01
- Volume
- 20
- Issue
- 19
- Pages
- 4083-4107
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159283488
- Cited by
- 417
- References
- 38
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.